Krise bei Gerresheimer: Umsatzeinbruch, Aktiencrash und Kostensenkungsprogramm Gewinnwarnungen und Stellenabbau: Gerresheimer kämpft gegen die Marktschwäche in der Kosmetikindustrie, nun folgt ein Kostensenkungsprogramm. Für den Standort in Pfreimd hört man aber zuversichtliche Worte aus Düsseldorf.

Gewinnwarnungen und Stellenabbau: #Gerresheimer kämpft gegen die Marktschwäche in der Kosmetikindustrie, nun folgt ein Kostensenkungsprogramm. Für den Standort in Pfreimd hört man aber zuversichtliche Worte aus Düsseldorf.

Gerresheimer Aktie nach dem Absturz eine Turnaround-Spekulation? Die Gerresheimer Aktie sucht nach ihrem Kurssturz einen Boden. Der Bereich am Freitag erreichten Allzeittief bei 26,02 Euro könnte hierbei eine Rolle spielen. In den letzten Tagen hat sich der

Gerresheimer Aktie nach dem Absturz eine Turnaround-Spekulation? ... www.4investors.de/nachrichten/... #gerresheimer #aktien #4investors

Click Subscribe #Gerresheimer #StockMarket #CFOChange #Investing #FinanceNews

Gerresheimer stock falls after ending takeover talks with PE investors Investing.com -- Gerresheimer shares dropped 3.5% after the company announced it has terminated discussions with private equity investors regarding a potential takeover offer, determining that continuing the talks would not benefit the company or its stakeholders. The German packaging manufacturer said it will instead accelerate a strategic review of its Moulded Glass business, with results to be presented at a Capital Markets Day scheduled for October 15, 2025. The company will also unveil a new, transparent business segmentation at the event. Gerresheimer has been engaged in discussions with private equity investors since early 2025 but concluded that pursuing these negotiations further wasn’t in the company’s best interest. Management plans to refocus on its growth strategy, with particular emphasis on biologics, systems and solutions. Despite ending the takeover talks, Gerresheimer reaffirmed its recently-adjusted medium-term guidance, maintaining a positive outlook on growth prospects. The company continues to expect mid-term organic revenue growth of 6-9% and an organic adjusted EBITDA margin of 23-25%. The upcoming Capital Markets Day is now positioned as the next significant catalyst for the stock as investors seek additional details about the company’s strategic direction following the abandoned takeover discussions. Jefferies analysts commented on the development, stating: "The CMD is now the key NT catalyst for investors to watch as we expect more clarity on the MT potential of the different business lines, and the future of the newly-combined Moulded Glass business." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With GXId making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed GXId alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including GXId, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is GXId poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #Gerresheimer #StockMarket #Investing #PrivateEquity #TakeoverTalks

#gerresheimer #merger-and-acquisition #conglomerate #packaging-company #medical-equipment #corporate-strategy #takeover #private-equity #finance #business-news #european-company #germany-industry #reuters

Gerresheimer jumps 7% after clarifying talks with KPS, Warburg ongoing Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #Gerresheimer #StockMarket #FinanceNews #TradingUpdates #InvestmentTips

Gerresheimer Aktie verliert stark: Analysten äußern Zweifel an Prognosen Gerresheimer Aktie im Kurssturz: In der letzten Woche noch in der Spitze bei 66,50 Euro notierend, rauscht der MDAX-Titel heute auf bis zu 47 Euro in die Tiefe. Der Grund: Schwache Zahlen, eine

Gerresheimer Aktie verliert stark: Analysten äußern Zweifel an Prognosen ... www.4investors.de/nachrichten/... #gerresheimer #aktien #4investors

Gerresheimer sees modest Q2 growth; shares drop 7% The company’s adjusted EBITDA margin is expected to be around 19% for the same period, compared to the previous year. For the full year 2025, Gerresheimer predicts organic revenue growth of 1-2%, with an EBITDA margin around 20%. This comes with a notable reduction in the company’s 2024 dividend, which has been adjusted from EUR 1.25 per share to EUR 0.04. Further adjustments to the 2025 outlook include an expected decrease in adjusted EPS in the low double-digit percentage range, compared to the previous year’s growth in a high single-digit percentage range. The company’s supervisory board will discuss the new dividend proposal on June 5, 2025. The board will also discuss the adjustments to the 2025 guidance, including the expected decline in adjusted EPS and the revised EBITDA margin of around 20%, a decrease from the previously projected 22%. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Gerresheimer #RevenueGrowth #FinancialNews #MarketTrends #Q22025

Gerresheimer sinks 11% after KKR exits takeover bid, Bloomberg report says Investing.com -- Shares of Gerresheimer AG (ETR:GXIG) plunged 11% on Friday after Bloomberg reported that KKR & Co (NYSE:KKR). pulled out of a private equity consortium that had been evaluating a potential takeover of the German packaging and medical technology company. The consortium, which initially included both KKR, a global investment firm, and Warburg Pincus, had expressed interest in buying Gerresheimer, which is known for manufacturing specialized medical packaging, including injector pens for weight-loss drugs such as Novo Nordisk’s Wegovy. Their non-binding bid, reportedly around 90 euros per share, valued the company at approximately €3.1 billion, the report said. Despite KKR’s exit, Warburg Pincus remains engaged in discussions and is reportedly still considering a path forward. Whether Warburg Pincus will attempt to proceed independently or seek new investment partners to revive the deal remains unclear. Gerresheimer’s management has yet to issue a statement addressing the latest developments, while KKR has not commented on the reasons behind its withdrawal. Warburg Pincus has also declined to comment. This abrupt shake-up follows Gerresheimer’s earlier acknowledgment in February that it was in preliminary discussions with private equity investors regarding a potential sale. At the time, the company clarified that any interest expressed was informal and non-binding.

Click Subscribe #Gerresheimer #KKR #Investing #StockMarket #TakeoverBid

Gerresheimer's Lasix ONYU Receives FDA Tentative Approval for Innovative Home Treatment Gerresheimer's Lasix ONYU, an innovative product for heart failure treatment, gains FDA Tentative Approval, enhancing remote patient care.

Gerresheimer's Lasix ONYU Receives FDA Tentative Approval for Innovative Home Treatment #Germany #FDA_Approval #Düsseldorf #Gerresheimer #Lasix_ONYU

#Gerresheimer Q1: Umsatz 466,1 Mio € (Prognose 463 Mio.€ / Vorjahr 457,8 Mio. €); bereinigtes EBITDA 80,9 Mio. € (Prognose 81 Mio. € / Vorjahr 78 Mio. €); Gewinn je Aktie 0,38 €; bereinigter Gewinn je Aktie 0,65 € (Prognose 0,68 € / Vorjahr 0,71 €) #Aktien #Börse #GXI

#Gerresheimer Prognose 2024 (bereinigt): Umsatzwachstum 5 bis 10 %; EBITDA 430 bis 450 Mio. €; Gewinnwachstum je Aktie 8 bis 12 % #Aktien #Börse #GXI #finsky